A disturbing cancer drug scam involving counterfeit versions of a life-saving immunotherapy treatment has come to light, exposing a dangerous network operating across hospitals and pharmacies in India. The case centres on Keytruda fake drug circulation, where fake vials of a high-cost cancer medicine were allegedly sold to vulnerable patients using authentic batch numbers and recycled packaging.
The drug at the heart of the controversy is Keytruda, an advanced immunotherapy manufactured by Merck & Co, widely used in the treatment of multiple cancers. With each vial costing over Rs 1.5 lakh, the demand for discounted alternatives has created opportunities for illegal operators in the Keytruda black market.
How the fake cancer medicine racket operates
Investigations into the fake cancer medicine network reveal a sophisticated system involving pharmacists, intermediaries, and alleged insiders within medical institutions. The scam relies on sourcing used vials, replicating packaging, and attaching genuine batch numbers to make counterfeit products appear authentic. These fake vials are then sold to patients at slightly reduced prices, making them attractive to families struggling with treatment costs.
In one case, a cancer patient undergoing treatment at Postgraduate Institute of Medical Education and Research reportedly purchased multiple vials of what was believed to be genuine medication. Authorities later found that the substances administered were not the prescribed immunotherapy but contained unrelated antifungal compounds, raising serious concerns about patient safety.
Hospital drug nexus under scrutiny
The unfolding hospital drug nexus has intensified scrutiny on supply chain practices within healthcare institutions. Investigators suggest that access to genuine packaging and batch information points to possible collusion beyond retail-level operators. The misuse of medical waste, including discarded vials, has further enabled the Keytruda fake drug racket to thrive.
Experts in pharmaceutical regulation indicate that such cancer drug scams are not isolated incidents but part of a broader pattern driven by high drug prices and weak enforcement. They emphasise the need for stricter tracking systems, including end-to-end verification of drug movement from manufacturer to patient.
Rising cancer burden fuels black market
India’s rapidly increasing cancer burden has created fertile ground for the Keytruda black market. Health experts project a significant rise in cancer cases over the coming decades, which, combined with the high cost of treatment, has intensified demand for affordable alternatives. This imbalance between affordability and availability is being exploited by criminal networks dealing in fake cancer medicine.
Medical professionals warn that the use of counterfeit drugs not only jeopardises treatment outcomes but can also lead to severe complications or death. They stress that patients should rely only on authorised supply channels and verify drug authenticity before use.
Responsibility and regulatory gaps
Merck & Co has indicated that ensuring the authenticity of drugs at the point of administration lies primarily with hospitals. However, policy experts argue that the responsibility must be shared across the entire supply chain, including manufacturers, distributors, and regulatory bodies.
The exposure of this cancer drug scam highlights significant gaps in oversight, particularly in monitoring high-value medications. Analysts believe that without robust safeguards, including digital tracking and stricter penalties, the Keytruda fake drug issue could persist.
What this means for patients
The emergence of the fake cancer medicine racket has shaken confidence in healthcare systems, especially among patients undergoing critical treatments. The hospital drug nexus not only undermines trust but also places lives at risk, making it imperative for authorities to act swiftly.
Experts recommend increased awareness, better verification protocols, and tighter regulatory enforcement to curb the spread of the Keytruda black market. As investigations continue, the case serves as a stark reminder of the vulnerabilities in the healthcare supply chain and the urgent need for reform.
Leave a Reply